"Scholarship in Pediatric Oncology" - AIRC Foundation - € 25,000
The UniCredit Foundation supports scientific research through scholarships. Pediatric lymphomas will be studied through the AIRC scholarship our contribution
In 2020, the UniCredit Foundation once again wished to confirm its support of scientific research by sponsoring a scholarship in partnership with the AIRC
€25,000 were awarded to the 2019 scholarship winner, researcher Nina Tanaskovic, for her project entitled, "Tumor suppressor activity of the polycombgroup ring finger protein PCGF6 in MYC - induced lymphoma," allowing her to continue studying pediatric lymphomas for the purpose of developing specific pediatric treatments.
Pediatric oncology patients are often treated using protocols designed for adults.
The UniCredit Foundation funds an annual renewable scholarship in the amount of €25,000. The winner works at the European Institute of Oncology IRCCS S.r.l. in Milan, conducting a study on the role of a specific protein (PCGF6) in regulating certain lymphoma genes that must be treated using pediatric therapies. The study, set to finish by the end of 2022, aims to assess and understand the working mechanism of the PCGF6 protein, which could be a fundamental first step in developing new treatment
strategies against this type of cancer.
The AIRC Foundation
The AIRC Foundation - The Italian Association for Cancer Institute to support cancer research.The Foundation supports innovative scientific projects, spreads scientific information andCancer Research was established in 1965 thanks to the initiative of some researchers from the Milan promotes the culture of prevention. It has 4.5 million supporters, 20,000 volunteers and 17 regional committees that guarantee about 5,000 researchers the resources to bring the results from the laboratory to the patient as quickly as possible.
One of the Foundation's objectives is to grow a new generation of scientists who are dedicated to cancer research in Italy, supporting training experiences at large research institutes, first in Italy and then abroad, to confront with the best cancer research in the world.